Levonorgestrel/Ethinylestradiol Eugia (Ethinylestradiol, Levonorgestrel)

The estrogen component (ethinylestradiol) and the progestogen component (levonorgestrel) together suppress the hypothalamic‑pituitary‑ovarian axis, preventing the luteinizing hormone surge needed for ovulation. They also thicken cervical mucus and modify the endometrium, creating multiple barriers to fertilization and implantation.

The dosing regimen is set by the prescribing healthcare professional based on the product’s strength and the patient’s clinical needs. Typically, one tablet is taken orally each day at the same time, but the exact schedule and duration are determined by the prescriber.

The product is classified as pregnancy category X, meaning it is contraindicated in known or suspected pregnancy. It is also not recommended for use while breastfeeding because hormonal exposure may affect milk production and infant hormone balance.

Enquiries can be submitted through the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levonorgestrel/Ethinylestradiol Eugia contains a standard dose of ethinylestradiol and levonorgestrel, a widely used progestogen. Its efficacy and safety profile are comparable to other EE/LEVO formulations, though individual tolerability may differ based on hormone sensitivity, pill composition and patient medical history.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

The medication is taken orally with a glass of water, usually at the same time each day. It should be swallowed whole; crushing or chewing the tablet may affect absorption and efficacy.

Serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, hepatic adenoma, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe headache, visual changes, or swelling of the limbs.

Women with known or suspected pregnancy, a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, certain hormone‑dependent cancers, or who are over 35 and smoke heavily should avoid this medication. It is also contraindicated in individuals with known hypersensitivity to any component of the tablet.